2023-01-012023-12-312023-12-31false12490885Xgenomes Limited2024-08-20iso4217:GBPxbrli:pure124908852023-01-01124908852023-12-31124908852023-01-012023-12-31124908852022-01-01124908852022-12-31124908852022-01-012022-12-3112490885bus:SmallEntities2023-01-012023-12-3112490885bus:AuditExempt-NoAccountantsReport2023-01-012023-12-3112490885bus:FullAccounts2023-01-012023-12-3112490885bus:PrivateLimitedCompanyLtd2023-01-012023-12-3112490885core:WithinOneYear2023-12-3112490885core:AfterOneYear2023-12-3112490885core:WithinOneYear2022-12-3112490885core:AfterOneYear2022-12-3112490885core:ShareCapital2023-12-3112490885core:SharePremium2023-12-3112490885core:RevaluationReserve2023-12-3112490885core:OtherReservesSubtotal2023-12-3112490885core:RetainedEarningsAccumulatedLosses2023-12-3112490885core:ShareCapital2022-12-3112490885core:SharePremium2022-12-3112490885core:RevaluationReserve2022-12-3112490885core:OtherReservesSubtotal2022-12-3112490885core:RetainedEarningsAccumulatedLosses2022-12-3112490885core:LandBuildings2023-12-3112490885core:PlantMachinery2023-12-3112490885core:Vehicles2023-12-3112490885core:FurnitureFittings2023-12-3112490885core:OfficeEquipment2023-12-3112490885core:NetGoodwill2023-12-3112490885core:IntangibleAssetsOtherThanGoodwill2023-12-3112490885core:ListedExchangeTraded2023-12-3112490885core:UnlistedNon-exchangeTraded2023-12-3112490885core:LandBuildings2022-12-3112490885core:PlantMachinery2022-12-3112490885core:Vehicles2022-12-3112490885core:FurnitureFittings2022-12-3112490885core:OfficeEquipment2022-12-3112490885core:NetGoodwill2022-12-3112490885core:IntangibleAssetsOtherThanGoodwill2022-12-3112490885core:ListedExchangeTraded2022-12-3112490885core:UnlistedNon-exchangeTraded2022-12-3112490885core:LandBuildings2023-01-012023-12-3112490885core:PlantMachinery2023-01-012023-12-3112490885core:Vehicles2023-01-012023-12-3112490885core:FurnitureFittings2023-01-012023-12-3112490885core:OfficeEquipment2023-01-012023-12-3112490885core:NetGoodwill2023-01-012023-12-3112490885core:IntangibleAssetsOtherThanGoodwill2023-01-012023-12-3112490885core:ListedExchangeTraded2023-01-012023-12-3112490885core:UnlistedNon-exchangeTraded2023-01-012023-12-3112490885core:MoreThanFiveYears2023-01-012023-12-3112490885core:Non-currentFinancialInstruments2023-12-3112490885core:Non-currentFinancialInstruments2022-12-3112490885dpl:CostSales2023-01-012023-12-3112490885dpl:DistributionCosts2023-01-012023-12-3112490885core:LandBuildings2023-01-012023-12-3112490885core:PlantMachinery2023-01-012023-12-3112490885core:Vehicles2023-01-012023-12-3112490885core:FurnitureFittings2023-01-012023-12-3112490885core:OfficeEquipment2023-01-012023-12-3112490885dpl:AdministrativeExpenses2023-01-012023-12-3112490885core:NetGoodwill2023-01-012023-12-3112490885core:IntangibleAssetsOtherThanGoodwill2023-01-012023-12-3112490885dpl:GroupUndertakings2023-01-012023-12-3112490885dpl:ParticipatingInterests2023-01-012023-12-3112490885dpl:GroupUndertakingscore:ListedExchangeTraded2023-01-012023-12-3112490885core:ListedExchangeTraded2023-01-012023-12-3112490885dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-01-012023-12-3112490885core:UnlistedNon-exchangeTraded2023-01-012023-12-3112490885dpl:CostSales2022-01-012022-12-3112490885dpl:DistributionCosts2022-01-012022-12-3112490885core:LandBuildings2022-01-012022-12-3112490885core:PlantMachinery2022-01-012022-12-3112490885core:Vehicles2022-01-012022-12-3112490885core:FurnitureFittings2022-01-012022-12-3112490885core:OfficeEquipment2022-01-012022-12-3112490885dpl:AdministrativeExpenses2022-01-012022-12-3112490885core:NetGoodwill2022-01-012022-12-3112490885core:IntangibleAssetsOtherThanGoodwill2022-01-012022-12-3112490885dpl:GroupUndertakings2022-01-012022-12-3112490885dpl:ParticipatingInterests2022-01-012022-12-3112490885dpl:GroupUndertakingscore:ListedExchangeTraded2022-01-012022-12-3112490885core:ListedExchangeTraded2022-01-012022-12-3112490885dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-01-012022-12-3112490885core:UnlistedNon-exchangeTraded2022-01-012022-12-3112490885core:NetGoodwill2023-12-3112490885core:IntangibleAssetsOtherThanGoodwill2023-12-3112490885core:LandBuildings2023-12-3112490885core:PlantMachinery2023-12-3112490885core:Vehicles2023-12-3112490885core:FurnitureFittings2023-12-3112490885core:OfficeEquipment2023-12-3112490885core:AfterOneYear2023-12-3112490885core:WithinOneYear2023-12-3112490885core:ListedExchangeTraded2023-12-3112490885core:UnlistedNon-exchangeTraded2023-12-3112490885core:ShareCapital2023-12-3112490885core:SharePremium2023-12-3112490885core:RevaluationReserve2023-12-3112490885core:OtherReservesSubtotal2023-12-3112490885core:RetainedEarningsAccumulatedLosses2023-12-3112490885core:NetGoodwill2022-12-3112490885core:IntangibleAssetsOtherThanGoodwill2022-12-3112490885core:LandBuildings2022-12-3112490885core:PlantMachinery2022-12-3112490885core:Vehicles2022-12-3112490885core:FurnitureFittings2022-12-3112490885core:OfficeEquipment2022-12-3112490885core:AfterOneYear2022-12-3112490885core:WithinOneYear2022-12-3112490885core:ListedExchangeTraded2022-12-3112490885core:UnlistedNon-exchangeTraded2022-12-3112490885core:ShareCapital2022-12-3112490885core:SharePremium2022-12-3112490885core:RevaluationReserve2022-12-3112490885core:OtherReservesSubtotal2022-12-3112490885core:RetainedEarningsAccumulatedLosses2022-12-3112490885core:NetGoodwill2022-01-0112490885core:IntangibleAssetsOtherThanGoodwill2022-01-0112490885core:LandBuildings2022-01-0112490885core:PlantMachinery2022-01-0112490885core:Vehicles2022-01-0112490885core:FurnitureFittings2022-01-0112490885core:OfficeEquipment2022-01-0112490885core:AfterOneYear2022-01-0112490885core:WithinOneYear2022-01-0112490885core:ListedExchangeTraded2022-01-0112490885core:UnlistedNon-exchangeTraded2022-01-0112490885core:ShareCapital2022-01-0112490885core:SharePremium2022-01-0112490885core:RevaluationReserve2022-01-0112490885core:OtherReservesSubtotal2022-01-0112490885core:RetainedEarningsAccumulatedLosses2022-01-0112490885core:AfterOneYear2023-01-012023-12-3112490885core:WithinOneYear2023-01-012023-12-3112490885core:Non-currentFinancialInstrumentscore:CostValuation2023-01-012023-12-3112490885core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-01-012023-12-3112490885core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-01-012023-12-3112490885core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-01-012023-12-3112490885core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-01-012023-12-3112490885core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-01-012023-12-3112490885core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-01-012023-12-3112490885core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-01-012023-12-3112490885core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-01-012023-12-3112490885core:Non-currentFinancialInstrumentscore:CostValuation2023-12-3112490885core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-12-3112490885core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-12-3112490885core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-12-3112490885core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-12-3112490885core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-12-3112490885core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-12-3112490885core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-12-3112490885core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-12-3112490885core:Non-currentFinancialInstrumentscore:CostValuation2022-12-3112490885core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-12-3112490885core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-12-3112490885core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-12-3112490885core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-12-3112490885core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-12-3112490885core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-12-3112490885core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-12-3112490885core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-12-3112490885bus:Director12023-01-012023-12-31

Xgenomes Limited

Registered Number
12490885
(England and Wales)

Unaudited Financial Statements for the Year ended
31 December 2023

Xgenomes Limited
Company Information
for the year from 1 January 2023 to 31 December 2023

Director

Dr K Mir

Registered Address

Building 423 - Sky View (Ro) Argosy Road
East Midlands Airport
Derby
DE74 2SA

Registered Number

12490885 (England and Wales)
Xgenomes Limited
Statement of Financial Position
31 December 2023

Notes

2023

2022

£

£

£

£

Fixed assets
Tangible assets38111,456
8111,456
Current assets
Debtors483,237161,149
Cash at bank and on hand19,1271,235
102,364162,384
Creditors amounts falling due within one year5(493,806)(246,033)
Net current assets (liabilities)(391,442)(83,649)
Total assets less current liabilities(391,361)(72,193)
Creditors amounts falling due after one year6(1,348,244)(1,367,845)
Net assets(1,739,605)(1,440,038)
Capital and reserves
Called up share capital11
Profit and loss account(1,739,606)(1,440,039)
Shareholders' funds(1,739,605)(1,440,038)
The financial statements were approved and authorised for issue by the Director on 20 August 2024, and are signed on its behalf by:
Dr K Mir
Director
Registered Company No. 12490885
Xgenomes Limited
Notes to the Financial Statements
for the year ended 31 December 2023

1.Accounting policies
Statutory information
XGenomes Limited is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006.
Basis of preparation
The financial statements have been prepared under the historical cost convention.
Functional and presentation currency
The financial statements are presented in pound sterling (£), which is the company’s functional currency, and figures are rounded to the nearest whole pound.
Going concern
The financial statements have been prepared on the going concern basis. The company incurred losses during the year, however the directors believe that the company has sufficient financial resources to be able to meet its obligations, if and when, they become due, and that the company can continue in operational existence for a period of at least 12 months from the statement of financial position date. On this basis, the directors are of the opinion that they should continue to adopt the going concern basis in preparing the annual financial statements.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The balance sheet is credited with the value of invoiced sales, as deferred income, which is then amortised to revenue over the period of the contract. At the balance sheet date, the carrying value of deferred income reflects the total value of invoiced sales which has not yet been recognised as revenue.
Revenue from rendering of services
Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
Operating leases
Rentals paid under operating leases are charged to the income statement on a straight line basis over the period of the lease.
Employee benefits
Contributions to defined contribution plans are expensed in the period to which they relate.
Defined contribution pension plan
The company operates a pension plan for the benefit of its employees. Contributions are recognised as expenses as they become payable. Differences between contributions payable in the year and those actually paid are recognised as either prepayments or accruals in the statement of financial position. The assets of the defined contribution pension scheme are held separately from those of the company in an independently administered fund.
Foreign currency translation
Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions. At each reporting period end, foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when the fair value was determined. Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at the period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the income statement.
Current taxation
Taxation for the period comprises current tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. Current taxation assets and liabilities are not discounted. Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date. Tax credits shown on the income statement represent tax credits received or receivable from HMRC as a result of claims made under HMRC’s R&D tax relief schemes.
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Research and development
Revenue expenditure on research and development is written off in the period in which it is incurred. The company's revenue exenditure on research and development often qualifies for relief under the various R&D tax relief schemes, including the SME R&D tax relief scheme and the Research and Development Expenditure Credit (RDEC) scheme. Tax Credits arising from successful claims under the SME R&D tax relief scheme are reflected 'below the line' as a reduction in the Corporation Tax charge or, if the company is loss making, as a Corporation Tax credit. Tax credits arising from successful claims under the RDEC scheme are subject to Corporation Tax. Gross benefits are therefore reflected 'above the line' in Other Income with the corresponding charge to Corporation Tax reflected as an increase in the Corporation Tax charge, or decrease in the Corporation Tax credit if appropriate. Tax credits receivable from R&D claims are recognised in the period in which the qualifying expenditure is incurred.
Tangible fixed assets and depreciation
Tangible assets are stated at cost (or deemed cost), less accumulated depreciation and accumulated impairment losses. Cost includes the original purchase price, costs directly attributable to bringing the asset to its working condition for its intended use, dismantling and restoration costs. Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Straight line (years)
Office Equipment3
Trade and other debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and on hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less.
Trade and other creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Financial instruments
The Company has chosen to adopt the Sections 11 and 12 of FRS 102 in respect of financial instruments. The Company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in non puttable ordinary shares. Debt instruments (other than those wholly repayable or receivable within one year), including loans and other accounts receivable and payable, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received. However, if the arrangements of a short term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or financed at a rate of interest that is not a market rate or in case of an out right short term loan not at market rate, the financial asset or liability is measured, initially, at the present value of the future cash flow discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost. Financial assets and liabilities are offset and the net amount reported in the Statement of Financial Position when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
2.Average number of employees

20232022
Average number of employees during the year34
3.Tangible fixed assets

Office Equipment

Total

££
Cost or valuation
At 01 January 2350,19950,199
At 31 December 2350,19950,199
Depreciation and impairment
At 01 January 2338,74338,743
Charge for year11,37511,375
At 31 December 2350,11850,118
Net book value
At 31 December 238181
At 31 December 2211,45611,456
4.Debtors: amounts due within one year

2023

2022

££
Other debtors81,064157,943
Prepayments and accrued income2,1733,206
Total83,237161,149
5.Creditors: amounts due within one year

2023

2022

££
Trade creditors / trade payables410,036236,417
Taxation and social security42,8179,394
Other creditors40,953222
Total493,806246,033
Included in trade creditors / trade payables is an amount of £203,781 which is due to a group undertaking.
6.Creditors: amounts due after one year

2023

2022

££
Amounts owed to related parties1,348,2441,367,845
Total1,348,2441,367,845
7.Operating lease commitments
Future minimum lease payments under non-cancellable operating leases fall due as follows: Within one year: £14,250 (2022: £13,200) Between two and five years: £nil (2022: £13,200)
8.Parent-subsidiary relationships
The ultimate controlling party is Xgenomes Corp, a company incorporated in the United States with its registered offices situated at 750 Main St, Cambridge, MA 02139, USA.